Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Aug 1991
Randomized Controlled Trial Multicenter Study Clinical TrialSuperiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
Trials of selective 5-hydroxytryptamine3 receptor antagonists have shown excellent antiemetic activity for chemotherapy containing cisplatin when compared with high-dose metoclopramide. There is little information about the efficacy of these new agents for chemotherapy other than for high-dose cisplatin. ⋯ There was no difference in the frequency of reported adverse events. We conclude that granisetron is more effective than dexamethasone plus prochlorperazine in patients who are receiving moderately emetogenic cytotoxic agents.